Table 3.
mRNA-LNPs in development or on the market.
| Name | Adaptation disease | Company |
|---|---|---|
| mRNA-1273 | SARS-CoV-2 | Moderna |
| CV7202 | CureVac AG | |
| BNT-162b1 | BioTech | |
| BNT-162b2 | ||
| BNT-1623 | ||
| Tozinameran | ||
| ARCT-021 | Arcturus | |
| mRNA-1647 | Cytomegalovirus infection | Moderna |
| mRNA-1443 | ||
| mRNA-1345 | Metabolic virus infection Canine parainfluenza virus infections |
Moderna |
| mRNA-1653 | ||
| mRNA-1440 | Infectious disease | Valera LLC |
| mRNA-1851 | ||
| mRNA-1325 | Zika virus infection | Moderna |
| mRNA-1893 | ||
| CV-7202 | Rabies infection | CureVac AG |
| mRNA-1388 | Chikungunya virus infection | Valera LLC |
| mRNA-1172 | Respiratory Syncytial Virus Infections | Moderna |